October 2004

All Stories

The Lancet on Vioxx

in Uncategorized | no responses

The Lancet with an editorial on Vioxx. Some choice words, implicating direct-to-consumer marketing:

. . . in their review paper specifically highlighting the cardiovascular sideeffect profile of COX-2 inhibitors. Concerns were shared by the FDA, who implemented labelling changes in 2002 to reflect the findings from the VIGOR trial.

However, even following these warnings, and in the face of mounting evidence for the cardiovascular side-effects of rofecoxib, ...

CNN news, brought to you by Ambien

in Uncategorized | no responses

Ambien is now sponsoring CNN news segments, as well as having an increased presence on CNN's web site:

Prescription sleep aid Ambien entered into a deal with CNN ad sales to sponsor the "Morning Papers" segment on CNN's NewsNight with Aaron Brown. CNN ad sales COO Greg D'Alba brokered the deal with Sanofi-Synthelabo, a member of global pharmaceutical company Sanofi-Aventis Group.

Under the multi-media partnership, Ambien will also ...

An upcoming nightmare

in Uncategorized | no responses

Chiron announced that it won't make the flu vaccine this year, because of problems at its plant in Britain. It had planned to supply 48 million of the 100 million doses this year . This is terrible news - more to come.

Update:
The press release from Chiron.

The FDA with their response:

The Centers for Disease Control and Prevention is convening its Advisory Committee on ...

Why colon cleansing and colonic irrigation doesn’t work and can be harmful to patients

in Uncategorized | 4 responses

A reader writes:

It's impossible to perform a Google or Yahoo search using the word "colon", and not get flooded with hits advertising "proprietary" herbal blends guaranteed to cleanse the colon. Is this really necessary? As the ordinary person reads through any of these sites, he is led to believe that most all of us have 10 to 40 lb. of compacted debris in our colons. The "scare literature" continues ...

Paying dearly

in Uncategorized | no responses

Dr. Centor links to a NY Times article asking whether the Vioxx findings are a class effect. He also ends condemning direct-to-consumer advertising:

I would hold Vioxx up as a clear example of the dangers of DCA. DCA tries to spur demand. It did. And now Merck will probably pay. And maybe some patients have paid dearly.

It starts

in Uncategorized | no responses

The first lawsuits are coming against Merck in wake of the Vioxx recall:

Nevels says her 34-year-old daughter, Shelly South, took Vioxx for 21/2 years before dying of a heart attack in November 2002. She claims Merck knew of the risks of Vioxx long before its announcement Thursday.

Also named in the suit is Dr. Waclaw Alex Dymek, the Carrollton physician who prescribed the drug to South. Nevels claims ...

The cost of evolving technology

in Uncategorized | no responses

A recent study has suggested that there has been increasing use of CT angiography in the diagnosis of pulmonary embolism:

A new study, published in the October 2004 American Journal of Roentgenology, shows that during a nine-month period in 1997 –1998, 81 patients underwent CT for suspected pulmonary embolism through the emergency department at University Hospitals of Cleveland. That number increased to 349 during the corresponding nine-month interval in ...

The empire strikes back

in Uncategorized | one response

Following up the previous piece detailing the Pfizer insider that broke ranks and supported drug reimportation, Pfizer seems to be taking some action:

Pfizer Vice President of Marketing Peter Rost, who has publicly supported the legalization of prescription drug reimportation, on Thursday said that the company has launched an investigation into his political activities . . .

. . . Seven members of Congress on Wednesday wrote to ...

Vioxx alternatives: What if you can’t take Celebrex or Bextra?

in Uncategorized | 3 responses

The common perception that is being trotted out as an alternative to Vioxx is switching to Pfizer's Bextra or Celebrex, the other COX-2 inhibitors out there. However, these medications cannot be taken in those with a sulfa allergy or hypersensitivity. This excludes a large percentage of the population - studies estimate approximately 3.5% have a reaction to a sulfa drug. So, what are your alternatives if you can't ...

The day after

in Uncategorized | no responses

Now that everyone has gotten over the initial news of the Vioxx recall, some of the more interesting analysis emerges.

The San Francisco Chronicle details how understaffed the FDA is:

Miceli said the FDA is woefully understaffed. And its guidelines often lead it to look only at the evidence presented by drug manufacturers, he said -- not at the further data that could have been generated.
Forbes goes

Kevin Pho, MD

See all in: Pho

Physician

See all in: Physician

Patient

See all in: Patient

Policy

See all in: Policy

Tech

See all in: Tech

Social Media

See all in: Social media